Endocrine Society Presses Congress on Diabetes Research Funding and Insulin Affordability
The Endocrine Society is pressing Congress to act on two diabetes priorities before the end of the year: reauthorizing the Special Diabetes Program and advancing the INSULIN Act. The request lands at a moment when diabetes care depends as much on public policy as it does on biology, because research infrastructure and medication access can disappear quickly when federal deadlines are allowed to lapse.
One deadline is immediate. Funding for the Special Diabetes Program expires on December 31, and without reauthorization, the research and treatment programs it supports would stop. The program channels money to type 1 diabetes research through the National Institute of Diabetes and Digestive and Kidney Diseases, while also supporting type 2 diabetes prevention and education programs for American Indian and Alaska Native communities through the Indian Health Service. Those are not abstract line items. They are the federal backbone for work that shapes how diabetes is studied, prevented, and managed in populations with very different risks and care barriers.
The policy stakes are especially sharp because diabetes is not a single disease with a single remedy. Type 1 diabetes depends on continued immunologic and mechanistic research, because understanding beta-cell destruction, glucose regulation, and future preventive approaches requires long-horizon funding. Type 2 diabetes prevention in American Indian and Alaska Native communities carries a different but equally urgent public health burden: sustained education, culturally grounded outreach, and access to prevention resources can alter disease trajectories long before complications develop. When a program like this is interrupted, the loss is not only bureaucratic. It can slow the pace of prevention and weaken continuity in communities that already face disproportionate diabetes risk.
The society is also urging passage of the INSULIN Act, bipartisan legislation designed to make insulin more affordable. The measure would extend the $35 monthly insulin co-pay cap, now available to Medicare beneficiaries, into the private insurance market. It would also create resources to help uninsured people obtain affordable insulin. For patients who depend on insulin every day, the policy question is painfully concrete: whether the medication that keeps them out of the hospital will remain financially reachable month after month.
Insulin access is a clinical issue before it is a political one. If a patient cannot reliably afford insulin, glycemic control deteriorates, acute metabolic decompensation becomes more likely, and the risk of emergency care rises. The burden then travels through the entire system—more urgent visits, more complications, more instability, and more avoidable harm. A copay cap does not solve every affordability problem, but it can lower the most immediate barrier for many insured patients and reduce the chance that treatment decisions are driven by cost rather than physiology.
The Senate Health, Education, Labor & Pensions Committee approved the INSULIN Act in July, but neither the full Senate nor the House has voted on it. That leaves the bill in a familiar and consequential limbo: advanced enough to show bipartisan support, unfinished enough that patients still cannot count on relief. The Endocrine Society has responded by launching an online advocacy campaign encouraging members to contact their representatives and senators. The organization is asking constituents to make diabetes a priority before the legislative calendar closes out the year.
This kind of advocacy matters because endocrine care sits at the intersection of chronic disease management, drug pricing, and federal research policy. Diabetes outcomes are influenced not only by insulin pharmacology, glucose monitoring, and nutrition counseling, but also by whether research programs remain funded and whether patients can actually obtain the therapies they are prescribed. When federal support is steady, researchers can pursue long-term questions about prevention, pathophysiology, and treatment. When access is stable, clinicians can focus on titration, adherence, and complication prevention instead of improvising around cost barriers.
A one-sentence reality sits underneath both legislative asks: without action, research stalls and insulin remains unaffordable for too many people.
The Endocrine Society’s message is aimed squarely at lawmakers, but its practical reach extends into exam rooms, diabetes education visits, and community health settings. Clinicians know how quickly a missing prescription can turn into hyperglycemia, dehydration, missed work, and emergency treatment. Researchers know how easily a funding gap can delay studies that would clarify disease mechanisms or refine prevention strategies. Patients know the simplest fact of all: a medicine does not help if it cannot be obtained.
Congress now faces two separate but related choices. Reauthorization of the Special Diabetes Program would preserve a research and prevention platform that has direct relevance for type 1 diabetes and for prevention efforts in American Indian and Alaska Native communities. Passage of the INSULIN Act would widen access protections beyond Medicare and offer support for uninsured people who need insulin to survive. Each proposal addresses a different weak point in diabetes care, and each carries immediate implications for clinical practice.
A second blunt reality follows from the calendar: once the December 31 expiration date passes, the Special Diabetes Program cannot simply keep operating on momentum alone.
The Endocrine Society is asking constituents to contact Congress through its advocacy campaign at endocrine.org/advocacy/take-action. The appeal reflects a broader truth in endocrinology: research progress and medication access are both part of diabetes care, and both depend on decisions made far outside the clinic.